Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $19.42 (market cap $8.95B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.6× Norwegian Cruise Line Holdings Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NCLH | VRTX | |
|---|---|---|
Market Cap | $8.95B | $121.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $529.59 |
52-Week Low | $14.79 | $366.54 |
Enterprise Value | $23.92B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $19.45, down slightly by 0.05%, with a neutral technical signal and bearish moving averages. The company reported revenue of $9.83B in 2025, with net income of $423.25M and a profit margin of 4.3%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.23 versus $0.15 expected. Analyst consensus is bullish with a $20.82 price target, and cash flow trends improved to a positive net of $19M in 2025.
The outlook for NCLH is cautiously optimistic, supported by earnings momentum and analyst buy ratings, but risks include high debt levels and macroeconomic sensitivity. Investment opportunity lies in continued operational recovery and potential upside to price targets, while volatility from fuel costs and travel demand poses challenges.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
